Integration of Genomic and Clinical Trial Data Enables Biomarker Hypothesis Generation by Clinical Development
Medidata experts will showcase the value of Medidata Rave Omics with Biomarker Discovery in Oncology:
- Expanding clinical development outcomes from hypothesis confirmation to iterative hypothesis generation.
- Streamlining data capture, linking, and analysis within the clinical study process to sharpen genomic insights and shorten drug development timelines.
- Applying machine learning and automated statistical methodology at an accessible level.
- Uncovering novel insights: including data quality concerns, genes linked to response and adverse events, and novel patient clusters.
Jason Mezey, PhD, Principal Researcher for Rave Omics, Medidata Solutions; Professor, Cornell University & Weill Cornell Medicine Ruthanna Davi, PhD, Sr. Director of Data Science, Medidata Solutions; Former Deputy Director, Division of Biometrics II, Office of Biostatistics, CDER, FDA
Ana Oromendia, PhD, Business Analytics Manager for Rave Omics,
Medidata's unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world. The Medidata Clinical Cloud® connects patients, physicians and life sciences professionals. Companies on the Medidata platform are individually and collaboratively reinventing the way research is done to create smarter, more precise treatments. For more information: www.mdsol.com
*The “Industry Expert Theater Presentation” is a series of hour-long
presentations from industry leaders sharing the latest in oncology
practices, products, services and technologies. Not an official
presentation of the meeting. Not sponsored, endorsed, or accredited by